Botulinum toxin A - Lipella Pharmaceuticals

Drug Profile

Botulinum toxin A - Lipella Pharmaceuticals

Alternative Names: Lipo-BoNT; Liposomal botulinum toxin A - Lipella Pharmaceuticals; Liposome encapsulated BoNT-A - Lipella; Lipotoxin - Lipella; LP-09; OnabotulinumtoxinA - Lipella

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Lipella Pharmaceuticals
  • Developer Buddhist Tzu Chi General Hospital; Lipella Pharmaceuticals
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Interstitial cystitis; Overactive bladder

Most Recent Events

  • 23 Mar 2017 Phase-II development for Overactive bladder is ongoing in Taiwan
  • 23 Mar 2017 Lipella's botulinum toxin-A licensed to an unknown company worldwide (Lipella Pharmaceuticals website, March 2017)
  • 01 Feb 2017 Buddhist Tzu Chi General Hospital completes a phase II trial in Interstitial cystitis (In adults, In the elderly) in Taiwan (Intravesicular) (NCT02247557)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top